Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy.

Kyrochristos ID, Ziogas DE, Roukos DH.

Med Res Rev. 2018 Nov 11. doi: 10.1002/med.21549. [Epub ahead of print] Review.

PMID:
30417574
2.

Precision in personalized prediction-based medicine.

Kyrochristos ID, Ziogas DE, Roukos DH.

Per Med. 2018 Nov;15(6):467-470. doi: 10.2217/pme-2018-0079. Epub 2018 Nov 2. No abstract available.

PMID:
30387685
3.

Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology.

Ziogas DE, Kyrochristos ID, Roukos DH.

Drug Discov Today. 2018 Nov;23(11):1848-1872. doi: 10.1016/j.drudis.2018.07.008. Epub 2018 Aug 2. Review.

PMID:
30077778
4.

Next-generation sequencing: from conventional applications to breakthrough genomic analyses and precision oncology.

Ziogas DE, Kyrochristos ID, Roukos DH.

Expert Rev Med Devices. 2018 Jan;15(1):1-3. doi: 10.1080/17434440.2017.1419059. Epub 2017 Dec 28. Review. No abstract available.

PMID:
29284319
5.

Novel translational therapeutic strategy by sequencing primary liver cancer genomes.

Glantzounis GK, Kyrochristos ID, Ziogas DE, Lykoudis EG, Roukos DH.

Future Oncol. 2017 May;13(12):1049-1052. doi: 10.2217/fon-2017-0087. Epub 2017 May 11. No abstract available.

PMID:
28492086
6.

Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine.

Roukos DH.

Drug Discov Today. 2017 Aug;22(8):1148-1164. doi: 10.1016/j.drudis.2017.03.014. Epub 2017 Apr 8. Review.

PMID:
28400153
7.

Identification of novel genes by whole-exome sequencing can improve gastric cancer precision oncology.

Lianos GD, Glantzounis GK, Bali CD, Katsios C, Roukos DH.

Future Oncol. 2017 Apr;13(10):883-892. doi: 10.2217/fon-2016-0430. Epub 2016 Nov 29.

PMID:
27897040
8.

Intratumor and circulating clonal heterogeneity shape the basis of precision breast cancer therapy.

Ziogas DE, Spiliotis J, Lykoudis EG, Zografos GC, Roukos DH.

Future Oncol. 2017 Jan;13(2):113-116. Epub 2016 Sep 1. No abstract available.

PMID:
27581662
9.

Targeting dynamics of subclones of GI, liver and pancreatic cancers.

Ziogas DE, Glantzounis G, Liakakos T, Roukos DH.

Expert Rev Gastroenterol Hepatol. 2016 Jul;10(7):773-6. doi: 10.1080/17474124.2016.1179578. Epub 2016 May 3. No abstract available.

PMID:
27143511
10.

Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies.

Roukos DH.

Drug Discov Today. 2016 Apr;21(4):663-73. doi: 10.1016/j.drudis.2016.02.008. Epub 2016 Feb 18. Review.

PMID:
26912452
11.

From standard to new genome-based therapy of gastric cancer.

Lianos GD, Mangano A, Cho WC, Roukos DH.

Expert Rev Gastroenterol Hepatol. 2015;9(8):1023-6. doi: 10.1586/17474124.2015.1060856. Epub 2015 Jun 24. Review.

PMID:
26108988
12.

Tumor heterogeneity-based resistance guides personalized cancer medicine.

Lianos GD, Mangano A, Rausei S, Katsios C, Roukos DH.

Future Oncol. 2014 Oct;10(12):1889-92. doi: 10.2217/fon.14.122. No abstract available.

PMID:
25386806
13.

Genome network medicine: new diagnostics and predictive tools.

Roukos DH.

Expert Rev Mol Diagn. 2013 Sep;13(7):643-6. doi: 10.1586/14737159.2013.820540. No abstract available.

PMID:
24063390
14.

Beyond BRCA1/2: polygenic, 'polyfunctional' molecular circuitry model to predict breast cancer risk.

Lianos GD, Zoras O, Roukos DH.

Biomark Med. 2013 Oct;7(5):675-8. doi: 10.2217/bmm.13.87. No abstract available.

15.

Cancer heterogeneity and signaling network-based drug target.

Roukos DH.

Pharmacogenomics. 2013 Aug;14(11):1243-6. doi: 10.2217/pgs.13.113. No abstract available.

PMID:
23930670
16.

Decoding coronary artery disease: somatic mosaicism and genomics for personal and population risk prediction.

Katsouras CS, Baltogiannis GG, Naka KK, Roukos DH, Michalis LK.

Biomark Med. 2013 Apr;7(2):189-92. doi: 10.2217/bmm.13.4. No abstract available.

PMID:
23547811
17.

From next-generation sequencing to nanopore sequencing technology: paving the way to personalized genomic medicine.

Ku CS, Roukos DH.

Expert Rev Med Devices. 2013 Jan;10(1):1-6. doi: 10.1586/erd.12.63. No abstract available.

PMID:
23278216
18.

Integrated clinical genomics: new horizon for diagnostic and biomarker discoveries in cancer.

Roukos DH.

Expert Rev Mol Diagn. 2013 Jan;13(1):1-4. doi: 10.1586/erm.12.132. No abstract available.

PMID:
23256697
19.

Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic?

Roukos DH.

Expert Rev Proteomics. 2012 Aug;9(4):349-53. doi: 10.1586/epr.12.37. No abstract available.

PMID:
22967071
20.

Clinical cancer genome and precision medicine.

Roukos DH, Ku CS.

Ann Surg Oncol. 2012 Nov;19(12):3646-50. doi: 10.1245/s10434-012-2542-9.

PMID:
22851046

Supplemental Content

Loading ...
Support Center